Selected article for: "cell lysate and inflammasome activation"

Author: Yen, Wei-Chen; Wu, Yi-Hsuan; Wu, Chih-Ching; Lin, Hsin-Ru; Stern, Arnold; Chen, Shih-Hsiang; Shu, Jwu-Ching; Tsun-Yee Chiu, Daniel
Title: Impaired inflammasome activation and bacterial clearance in G6PD deficiency due to defective NOX/p38 MAPK/AP-1 redox signaling
  • Document date: 2019_11_2
  • ID: 6fw4thkq_39
    Snippet: G6PD-kd THP-1 cells expressed approximately 21.7% of the G6PD levels in the control THP-1 cells (Fig. 2A) . According to the results of MTT assay and the Cell Counting Kit-8 (CCK8), cell viability was similar between control and G6PD-kd THP-1 cells (Fig. S1 ). Similar to that observed in PBMCs from G6PD-deficient patients (Fig. 1B) , G6PD-kd THP-1 cells had decreased IL-1β secretion upon inflammasome activation (Fig. 2B) , and the pattern of pro.....
    Document: G6PD-kd THP-1 cells expressed approximately 21.7% of the G6PD levels in the control THP-1 cells (Fig. 2A) . According to the results of MTT assay and the Cell Counting Kit-8 (CCK8), cell viability was similar between control and G6PD-kd THP-1 cells (Fig. S1 ). Similar to that observed in PBMCs from G6PD-deficient patients (Fig. 1B) , G6PD-kd THP-1 cells had decreased IL-1β secretion upon inflammasome activation (Fig. 2B) , and the pattern of protein expression in the cell lysates and supernatants was the same as that found by ELISA (Fig. 2C) . The quantitative intensity of IL-1β in the cell lysate and supernatant is shown in Fig. 2D and E, respectively. The activity of G6PD was positively correlated with the secretion of IL-1β (Fig. 2F ).

    Search related documents:
    Co phrase search for related documents
    • cell lysate and inflammasome activation: 1, 2, 3
    • cell lysate and protein expression: 1, 2, 3, 4, 5, 6, 7, 8
    • cell lysate and supernatant cell lysate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • cell viability and control cell: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23
    • cell viability and inflammasome activation: 1, 2, 3
    • cell viability and MTT assay: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • cell viability and protein expression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • cell viability and secretion decrease: 1
    • control cell and inflammasome activation: 1
    • control cell and MTT assay: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • control cell and protein expression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • control cell and quantitative intensity: 1
    • inflammasome activation and MTT assay: 1
    • inflammasome activation and protein expression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
    • inflammasome activation and quantitative intensity: 1, 2
    • inflammasome activation and supernatant cell lysate: 1, 2, 3
    • MTT assay and protein expression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24
    • protein expression and secretion decrease: 1, 2
    • protein expression and supernatant cell lysate: 1